



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**Available online at: <http://www.iajps.com>

Research Article

**ANALYSIS OF NEURO DEGENERATION IN GLAUCOMA
PATIENTS BY TRANSPLANTED DIFFERENT CELL
PRECURSORS**Muhammad Arslan Iqbal¹, Adeeb Hussain², Sakhawat Ali²

Bahawalpur Victoria Hospital

District Headquarter Hospital Skardu

Abstract:

Introduction: Glaucoma is a common neurodegenerative disease for which current therapies are often insufficient. The purpose of our investigation was to determine whether oligodendrocyte precursor cells (OPCs), a type of neural stem cell, can protect retinal ganglion cells (RGCs) from glaucomatous damage in vivo. **Methods:** Intraocular pressure was chronically increased by trabecular laser treatment delivered unilaterally to adult rat eyes. OPCs were isolated in vitro and then transplanted intravitreally either before, or concurrent with, injury induction. **Results:** Transplanted OPCs were found to survive within the eye for at least 12 weeks and to localize close to the RGCs. Moreover, OPCs significantly enhanced the survival of RGCs in the glaucomatous eye, but only when concomitantly activated by inflammation. Amelioration of RGC death was not attributable to inflammation but relied on an interaction between inflammatory cells and OPCs. Engrafted cells also displayed multipotentiality in vivo.

Corresponding author:Muhammad Arslan Iqbal,
Bahawalpur Victoria Hospital

QR code



Please cite this article in press Muhammad Arslan Iqbal et al., *Analysis Of Neuro Degeneration In Glaucoma Patients By Transplanted Different Cell Precursors.*, Indo Am. J. P. Sci, 2019; 06(11).

INTRODUCTION:

Glaucoma is still one of the leading causes of blindness worldwide. In England and Wales glaucoma is a major or contributing factor in 12-14 % of all registrations for blindness and partial sight, only to macular degeneration¹. The worldwide burden is greater with glaucoma is the second leading cause of global blindness after cataract². It has been estimated that almost 60.5 million people worldwide affected by glaucoma in 2010, with the figure expected to rise to 80 million by 2020³.

A neurodegenerative disease known as glaucoma, which is caused by the gradual occurring death of retinal ganglion cells (rGCS). The pathophysiological changes can share with other neurodegenerative diseases, including axonal transport dysfunction, oxidative stress⁴ increased the level of intraocular pressure (IOP) is the main risk factor and depression in the level of IOP is the only cure for this particular disease. Whereas decreased levels of IOP cannot suppress RGC degeneration in some patients with glaucoma, so there may be a new method of treatment to protect RGC⁵. Stem cell technology is a newer tool in the treatment of neuroprotective treatment in the degeneration of CNS disease, then the increases neurodegeneration in the supply of neurotrophic factors. There is abundance oligodendrocyte precursor cells (OPCs) in the central nervous system (CNS) of adult individuals, where they are the most widely used type of proliferative cell⁵.

OPCs hold great responsibility for the generation of oligo dendrocytes in the developmental stage, whereas in adult individuals, they play a vital role in demyelinating pathologies and remyelinating of axon⁶. OPCs appear to contain the majority of the stem cell characteristics and has been shown to be neuroprotective *in vitro*⁷.

The aim of our study was to determine whether oligodendrocyte precursor cells (OPC), a type of neural stem cell can protect retinal ganglion cells (rGCS) from glaucomatous damage *in vivo*. Current treatments for glaucoma include lowering of intraocular pressure by eye drops, laser procedures or drainage surgery. However, as shown by the statistics above, many patients experience significant vision loss due to degeneration of retinal ganglion cells (rGCS) despite advances in the treatments currently available. The need for new treatment options exist for these patients, especially those with end-stage glaucoma, where the maintenance of a small number

of survivors rGCS perhaps even ensure a reasonable quality of life. Stem cell treatment developed in the laboratory and translated into clinical practice provides an exciting and realistic hope for those affected by degenerative retinal diseases⁸.

MATERIAL AND METHODS:**Preparation of Culture Medium**

First of all, primary mixed glial cultures generated from the cortex dissected from postnatal day 0 Lewis rat pups and grown on poly-D - lysine - coated tissue culture flasks in DMEM and 1% penicillin / streptomycin. OPC was isolated from the mixed glial cultures by a series of mechanical shaking steps and then kept in OPC expansion medium and analyzed directly after isolation.

Design of animal models

All animal experiments were conducted in accordance with the ethics committee university. Young adult (8 weeks old) male Lewis rats were used (n = 83). Animals had free access to food and water and were maintained on a 12 - hour light / dark cycle.

Experimental Design

Transplantation of naive OPCs were performed either at the time of glaucoma induction (acute group), or 8 weeks prior to (chronic group). A group experienced transplantation of activated OPCs 8 weeks before glaucoma induction and the OPC acute transplant experiment, the animals received one unioocular 3UL intra- vitreous injection of PBS alone.

RESULTS:

According to Figure 1 oligo dendrocyte progenitor cell (OPC) culture were analyzed for expression of A2B5 explaining the purity of the culture prior to transplantation. A2B5 is a cell surface antigen expressed by immature OPCs in culture (23). Immuno- cytochemical analysis showed that $93.9 \pm 2.9 \%$ (mean \pm SD, n = 7) of the transplanted cells was OPCs. In addition, the OPC cell cultures show appropriate morphology in culture. Immuno- cytochemical labeling of either ED1 or GFAP in OPC cultures showed a $2.37 \pm 1.9 \%$ (mean \pm SD) contamination of microglia and $2.34 \pm 0.9\%$ (mean \pm SD) contamination of astrocytes, respectively. Parallel staining in microglial cultures showed $1.15 \pm 1.2\%$ (mean \pm SD) contamination of OPCs and $0.84 \pm 0.6 \%$ (mean \pm SD) contamination of astrocytes.




Figure 1. Characterization of OPCs cultured for transplantation.



Figure 2: Intravitreal transplantation of OPCs did not affect intraocular pressure changes following ocular hypertension induction.

Table 2: Experimental Glaucoma Group

Group	Peak (mmHg)
Acute transplant	23±1.8
Chronic transplant	28±2.3

Peak IOP measurements were similar in the chronic OPC and OPC enabled transplantation experiments in which laser treatment was initiated at 16 weeks but significantly lower in the acute OPC transplantation experiment in which glaucoma was induced at 8 weeks of age.

DISCUSSION:

In the present study, we found that intra-vitreous transplantation of OPCs protected rGCS from glaucoma-induced death *in vivo*, but not until the engrafted cells had been activated by co-stimulation

of inflammatory cells. Thus, we can deduce that the grafted OPCs were responsible for reducing RGC loss, rather than neuroprotection occurs as a side effect of inflammatory processes⁹.

This is a key point that cytokine activated astrocyte can support injured neurons. However, the inflammatory stimulus was needed to induce OPC mediated neuroprotection as we also found that OPCs injected into the eye does not remedy glaucomatous neuronal degeneration. These results indicate that neuroprotection was mediated by the engrafted OPCs and it was triggered by a signal or signals transmitted by reactive immune cells. It seems unlikely that OPCs responded directly to zymosan, where they seem to lack TLR2, the innate receptor responsible for detecting zymosan, and failed to respond to zymosan exposure *in vitro*¹⁰.

CONCLUSION:

We have demonstrated that transplantation of OPCs may relieve RGC death *in vivo* and that this neuroprotective capacity depends on inflammatory cell activation of OPCs. Such long-term relief of RGC death in glaucoma at an experimental intervention is rarely seen, suggesting a new approach to the development of neuroprotective strategy.

REFERENCES:

1. Evans, M.J., Kaufman, M.H., 1981. Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292, 154-156.
2. Hemmati-Brivanlou, A., Melton, D., 1997. Vertebrate embryonic cells will become nerve cells unless told otherwise. *Cell* 88, 13-17.
3. Bunce C., Xing, W., Wormald, R., 2010. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. *Eye (Lond)* 24, 1692-1699.
4. Resnikoff, S., Pascolini, D., Etya'ale, D., Kocur, I., Pararajasegaram, R., Pokharel, G.P., Mariotti, S.P., 2004. Global data on visual impairment in the year 2002. *Bull World Health Organ* 82, 844-851.
5. Hentze, H., Graichen, R., Colman, A., 2007. Cell therapy and the safety of embryonic stem cell derived grafts. *Trends Biotechnol* 25, 24-32.
6. Moon, S.H., Kim, J.S., Park, S.J., Lim, J.J., Lee, H.J., Lee, S.M., Chung, H.M., 2011. Effect of chromosome instability on the maintenance and differentiation of human embryonic stem cells *in vitro* and *in vivo*. *Stem Cell Res* 6, 50-59.
7. Hirano, M., Yamamoto, A., Yoshimura, N., Tokunaga, T., Motohashi, T., Ishizaki, K., Yoshida, H., Okazaki, K., Yamazaki, H., Hayashi,

- S., Kunisada, T., 2003.Generation of structures formed by lens and retinal cells differentiating from embryonic stem cells. *Dev Dyn* 228, 664-671.
8. Martin KR, Quigley HA, Valenta D, Kielczewski J, Pease ME. Optic nerve dynein motor protein distribution changes with intraocular pressure elevation in a rat model of glaucoma. *Exp Eye Res.* 2006; 83: 255–262.
 9. Osakada, F., Ikeda, H., Sasai, Y., Takahashi, M., 2009. Stepwise differentiation of pluripotent stem cells into retinal cells. *Nat Protoc* 4, 811-824.
 10. Kumar DM, Agarwal N. Oxidative stress in glaucoma: a burden of evidence. *J Glaucoma.* 2007; 16:334 –343.